

60  
Cambridge

Observed and Expected Case Counts, with Standardized Incidence Ratios, 1998-2002

	Obs	Exp	SIR	95% CI		Obs	Exp	SIR	95% CI
Bladder, Urinary					Melanoma of Skin				
Male	52	71.4	72.8	(54.4-95.5)	Male	40	41.3	96.9	(69.2-131.9)
Female	28	29.9	93.7	(62.3-135.5)	Female	31	39.5	78.5	(53.3-111.4)
Brain and Other Nervous System					Multiple Myeloma				
Male	10	16.7	60.0	(28.7-110.3)	Male	9	10.1	89.2	(40.7-169.4)
Female	14	14.8	94.9	(51.8-159.3)	Female	8	9.3	86.1	(37.1-169.6)
Breast					Non-Hodgkin Lymphoma				
Male	3	2.2	nc	(nc-nc)	Male	26	40.6	64.1	(41.9-93.9)
Female	321	326.5	98.3	(87.8-109.7)	Female	34	39.3	86.5	(59.9-120.9)
Cervix Uteri					Oral Cavity & Pharynx				
Female	10	17.7	56.6	(27.1-104.0)	Male	32	28.8	110.9	(75.9-156.6)
Colon / Rectum					Female	12	15.9	75.3	(38.9-131.6)
Male	100	111.4	89.8	(73.1-109.2)	Ovary				
Female	93	122.1	76.2	(61.5-93.3)	Female	38	33.9	112.1	(79.3-153.9)
Esophagus					Pancreas				
Male	12	17.5	68.6	(35.4-119.9)	Male	22	20.6	106.7	(66.8-161.5)
Female	6	6.0	100.2	(36.6-218.1)	Female	28	25.1	111.4	(74.0-161.0)
Hodgkin Lymphoma					Prostate				
Male	10	10.8	92.8	(44.4-170.7)	Male	327	289.1	113.1	(101.2-126.1)
Female	4	9.0	nc	(nc-nc)	Stomach				
Kidney & Renal Pelvis					Male	18	19.1	94.3	(55.9-149.1)
Male	27	29.7	91.0	(60.0-132.4)	Female	18	13.1	137.2	(81.3-216.9)
Female	21	21.7	96.6	(59.8-147.7)	Testis				
Larynx					Male	15	21.2	70.6	(39.5-116.4)
Male	16	13.1	122.5	(70.0-199.0)					

Female	1	3.8	nc	(nc-nc)
Leukemia				
Male	19	24.3	78.1	(47.0-122.0)
Female	23	21.9	105.0	(66.5-157.6)
Liver and Intrahepatic Bile Ducts				
Male	10	13.8	72.7	(34.8-133.7)
Female	9	5.9	153.4	(70.0-291.2)
Lung and Bronchus				
Male	117	139.8	83.7	(69.2-100.3)
Female	111	136.6	81.3	(66.9-97.9)

Thyroid				
Male	12	9.6	124.7	(64.4-217.9)
Female	34	34.0	100.1	(69.3-139.8)
Uteri Corpus and Uterus, NOS				
Female	73	63.2	115.5	(90.6-145.3)
All Sites / Types				
Male	935	998.2	93.7	(87.8-99.9)
Female	987	1065.9	92.6	(86.9-98.6)

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ( (Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- Shading indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

61  
Canton

Observed and Expected Case Counts, with Standardized Incidence Ratios, 1998-2002

	Obs	Exp	SIR	95% CI
Bladder, Urinary				
Male	23	23.6	97.5	(61.8-146.3)
Female	14	9.5	147.9	(80.8-248.2)
Brain and Other Nervous System				
Male	4	4.4	nc	(nc-nc)
Female	4	4.0	nc	(nc-nc)
Breast				
Male	0	0.7	nc	(nc-nc)
Female	92	95.0	96.8	(78.1-118.7)
Cervix Uteri				

	Obs	Exp	SIR	95% CI
Melanoma of Skin				
Male	13	11.9	109.5	(58.3-187.3)
Female	7	9.9	70.6	(28.3-145.4)
Multiple Myeloma				
Male	2	3.3	nc	(nc-nc)
Female	3	2.9	nc	(nc-nc)
Non-Hodgkin Lymphoma				
Male	12	11.7	102.4	(52.8-178.8)
Female	13	11.6	112.4	(59.8-192.3)
Oral Cavity & Pharynx				

Colon / Rectum	Female	5	4.3	116.3	(37.5-271.4)	Male	7	8.9	78.3	(31.4-161.3)
	Male	37	36.4	101.7	(71.6-140.2)	Female	2	4.7	nc	(nc-nc)
	Female	56	39.0	143.7	(108.6-186.6)	Ovary				
Esophagus	Male	6	5.7	104.7	(38.2-228.0)	Female	8	9.8	81.9	(35.3-161.4)
	Female	6	1.9	314.5	(114.8-684.5)	Pancreas				
	Male	6	1.9	314.5	(114.8-684.5)	Male	12	6.8	177.3	(91.5-309.7)
Hodgkin Lymphoma	Male	6	1.8	325.7	(118.9-709.0)	Female	12	8.1	148.1	(76.4-258.6)
	Female	3	1.6	nc	(nc-nc)	Prostate				
	Male	6	1.8	325.7	(118.9-709.0)	Male	115	97.0	118.5	(97.9-142.3)
Kidney & Renal Pelvis	Female	3	1.6	nc	(nc-nc)	Stomach				
	Male	16	9.4	170.9	(97.6-277.5)	Male	3	6.2	nc	(nc-nc)
	Female	8	6.6	121.6	(52.4-239.6)	Female	4	4.2	nc	(nc-nc)
Larynx	Male	3	4.3	nc	(nc-nc)	Testis				
	Female	2	1.2	nc	(nc-nc)	Male	1	3.1	nc	(nc-nc)
	Male	3	4.3	nc	(nc-nc)	Thyroid				
Leukemia	Female	2	1.2	nc	(nc-nc)	Male	1	2.2	nc	(nc-nc)
	Male	8	7.2	111.8	(48.1-220.4)	Female	11	7.2	152.1	(75.8-272.1)
	Female	8	6.5	123.9	(53.4-244.2)	Uteri Corpus and Uterus, NOS				
Liver and Intrahepatic Bile Ducts	Male	3	4.3	nc	(nc-nc)	Female	17	18.7	90.9	(52.9-145.5)
	Female	4	1.8	nc	(nc-nc)	All Sites / Types				
	Male	3	4.3	nc	(nc-nc)	Male	321	315.7	101.7	(90.9-113.4)
Lung and Bronchus	Female	4	1.8	nc	(nc-nc)	Female	355	314.7	112.8	(101.4-125.2)
	Male	35	46.3	75.6	(52.6-105.1)					
	Female	52	42.8	121.4	(90.7-159.2)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ( (Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;

- Shading indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

62  
Carlisle

Observed and Expected Case Counts, with Standardized Incidence Ratios, 1998-2002

	Obs	Exp	SIR	95% CI		Obs	Exp	SIR	95% CI
Bladder, Urinary					Melanoma of Skin				
Male	4	4.6	nc	(nc-nc)	Male	3	2.7	nc	(nc-nc)
Female	1	1.4	nc	(nc-nc)	Female	3	2.0	nc	(nc-nc)
Brain and Other Nervous System					Multiple Myeloma				
Male	2	1.0	nc	(nc-nc)	Male	0	0.7	nc	(nc-nc)
Female	1	0.8	nc	(nc-nc)	Female	0	0.4	nc	(nc-nc)
Breast					Non-Hodgkin Lymphoma				
Male	0	0.2	nc	(nc-nc)	Male	1	2.5	nc	(nc-nc)
Female	31	19.6	158.1	(107.4-224.4)	Female	1	1.8	nc	(nc-nc)
Cervix Uteri					Oral Cavity & Pharynx				
Female	0	0.9	nc	(nc-nc)	Male	3	2.3	nc	(nc-nc)
Colon / Rectum					Female	0	0.9	nc	(nc-nc)
Male	2	7.4	nc	(nc-nc)	Ovary				
Female	3	5.3	nc	(nc-nc)	Female	2	1.9	nc	(nc-nc)
Esophagus					Pancreas				
Male	0	1.3	nc	(nc-nc)	Male	0	1.4	nc	(nc-nc)
Female	0	0.3	nc	(nc-nc)	Female	1	1.1	nc	(nc-nc)
Hodgkin Lymphoma					Prostate				
Male	0	0.4	nc	(nc-nc)	Male	22	22.6	97.5	(61.1-147.6)
Female	1	0.3	nc	(nc-nc)	Stomach				
Kidney & Renal Pelvis					Male	0	1.2	nc	(nc-nc)
Male	1	2.2	nc	(nc-nc)					

Larynx	Female	1	1.2	nc	(nc-nc)	Testis	Female	0	0.5	nc	(nc-nc)
	Male	0	1.0	nc	(nc-nc)		Male	1	0.6	nc	(nc-nc)
Leukemia	Female	0	0.2	nc	(nc-nc)	Thyroid					
	Male	1	1.5	nc	(nc-nc)		Male	0	0.5	nc	(nc-nc)
	Female	0	1.0	nc	(nc-nc)		Female	0	1.6	nc	(nc-nc)
Liver and Intrahepatic Bile Ducts						Uteri Corpus and Uterus, NOS					
	Male	0	1.0	nc	(nc-nc)						
	Female	0	0.3	nc	(nc-nc)		Female	1	3.9	nc	(nc-nc)
Lung and Bronchus						All Sites / Types					
	Male	3	9.7	nc	(nc-nc)		Male	50	69.1	72.4	(53.7-95.4)
	Female	4	7.0	nc	(nc-nc)		Female	51	55.9	91.3	(68.0-120.0)

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ( (Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- Shading indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

63  
Carver

Observed and Expected Case Counts, with Standardized Incidence Ratios, 1998-2002

	Obs	Exp	SIR	95% CI		Obs	Exp	SIR	95% CI
Bladder, Urinary					Melanoma of Skin				
Male	16	12.8	124.9	(71.4-202.9)	Male	7	6.4	109.9	(44.0-226.4)
Female	6	4.4	135.4	(49.4-294.8)	Female	6	4.9	122.4	(44.7-266.5)
Brain and Other Nervous System					Multiple Myeloma				
Male	3	2.4	nc	(nc-nc)	Male	2	1.8	nc	(nc-nc)
Female	1	2.0	nc	(nc-nc)	Female	1	1.4	nc	(nc-nc)
Breast					Non-Hodgkin Lymphoma				

Male	0	0.4	nc	(nc-nc)
Female	36	46.8	76.9	(53.8-106.4)
Cervix Uteri				
Female	2	2.2	nc	(nc-nc)
Colon / Rectum				
Male	16	19.7	81.4	(46.5-132.2)
Female	27	18.1	149.0	(98.2-216.8)
Esophagus				
Male	7	3.0	232.1	(93.0-478.2)
Female	2	0.9	nc	(nc-nc)
Hodgkin Lymphoma				
Male	1	1.0	nc	(nc-nc)
Female	0	0.9	nc	(nc-nc)
Kidney & Renal Pelvis				
Male	9	5.0	181.7	(82.9-345.0)
Female	7	3.2	218.0	(87.4-449.3)
Larynx				
Male	2	2.2	nc	(nc-nc)
Female	0	0.6	nc	(nc-nc)
Leukemia				
Male	6	3.9	153.2	(55.9-333.4)
Female	5	3.1	161.2	(52.0-376.2)
Liver and Intrahepatic Bile Ducts				
Male	1	2.3	nc	(nc-nc)
Female	1	0.9	nc	(nc-nc)
Lung and Bronchus				
Male	21	24.6	85.4	(52.8-130.5)
Female	29	20.8	139.7	(93.6-200.7)

Male	10	6.3	157.8	(75.5-290.2)
Female	5	5.6	89.2	(28.8-208.2)
Oral Cavity & Pharynx				
Male	8	4.7	169.5	(73.0-334.1)
Female	2	2.2	nc	(nc-nc)
Ovary				
Female	6	4.8	125.9	(46.0-274.1)
Pancreas				
Male	6	3.6	164.5	(60.1-358.0)
Female	8	3.7	213.3	(91.9-420.4)
Prostate				
Male	48	49.3	97.5	(71.8-129.2)
Stomach				
Male	4	3.4	nc	(nc-nc)
Female	4	1.9	nc	(nc-nc)
Testis				
Male	1	1.6	nc	(nc-nc)
Thyroid				
Male	4	1.2	nc	(nc-nc)
Female	4	3.7	nc	(nc-nc)
Uteri Corpus and Uterus, NOS				
Female	7	9.1	77.3	(31.0-159.2)
All Sites / Types				
Male	190	166.8	113.9	(98.3-131.3)
Female	173	152.1	113.7	(97.4-132.0)

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ( (Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- Shading indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

64

Charlemont

Observed and Expected Case Counts, with Standardized Incidence Ratios, 1998-2002

	Obs	Exp	SIR	95% CI		Obs	Exp	SIR	95% CI
Bladder, Urinary					Melanoma of Skin				
Male	1	1.4	nc	(nc-nc)	Male	0	0.7	nc	(nc-nc)
Female	1	0.5	nc	(nc-nc)	Female	0	0.6	nc	(nc-nc)
Brain and Other Nervous System					Multiple Myeloma				
Male	0	0.3	nc	(nc-nc)	Male	1	0.2	nc	(nc-nc)
Female	0	0.2	nc	(nc-nc)	Female	0	0.1	nc	(nc-nc)
Breast					Non-Hodgkin Lymphoma				
Male	0	0.0	nc	(nc-nc)	Male	0	0.7	nc	(nc-nc)
Female	5	5.4	92.9	(29.9-216.7)	Female	0	0.6	nc	(nc-nc)
Cervix Uteri					Oral Cavity & Pharynx				
Female	0	0.3	nc	(nc-nc)	Male	0	0.6	nc	(nc-nc)
					Female	0	0.3	nc	(nc-nc)
Colon / Rectum					Ovary				
Male	2	2.1	nc	(nc-nc)					
Female	3	1.9	nc	(nc-nc)	Female	1	0.5	nc	(nc-nc)
Esophagus					Pancreas				
Male	0	0.4	nc	(nc-nc)	Male	2	0.4	nc	(nc-nc)
Female	0	0.1	nc	(nc-nc)	Female	1	0.4	nc	(nc-nc)
Hodgkin Lymphoma					Prostate				
Male	0	0.1	nc	(nc-nc)	Male	6	6.0	99.9	(36.5-217.5)
Female	0	0.1	nc	(nc-nc)					

Kidney & Renal Pelvis						Stomach					
Male	0	0.6	nc	(nc-nc)		Male	0	0.4	nc	(nc-nc)	
Female	0	0.3	nc	(nc-nc)		Female	0	0.2	nc	(nc-nc)	
Larynx						Testis					
Male	0	0.3	nc	(nc-nc)		Male	1	0.2	nc	(nc-nc)	
Female	0	0.1	nc	(nc-nc)							
Leukemia						Thyroid					
Male	1	0.4	nc	(nc-nc)		Male	0	0.1	nc	(nc-nc)	
Female	0	0.3	nc	(nc-nc)		Female	0	0.4	nc	(nc-nc)	
Liver and Intrahepatic Bile Ducts						Uteri Corpus and Uterus, NOS					
Male	0	0.3	nc	(nc-nc)							
Female	0	0.1	nc	(nc-nc)		Female	0	1.1	nc	(nc-nc)	
Lung and Bronchus						All Sites / Types					
Male	2	2.8	nc	(nc-nc)		Male	16	19.1	83.7	(47.8-135.9)	
Female	4	2.2	nc	(nc-nc)		Female	16	16.8	95.3	(54.4-154.7)	

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ( (Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- Shading indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

65  
Charlton

Observed and Expected Case Counts, with Standardized Incidence Ratios, 1998-2002

	Obs	Exp	SIR	95% CI		Obs	Exp	SIR	95% CI
Bladder, Urinary					Melanoma of Skin				
Male	8	8.0	99.6	(42.9-196.2)	Male	0	4.9	nc	(nc-nc)
Female	3	2.8	nc	(nc-nc)	Female	2	4.1	nc	(nc-nc)
Brain and Other Nervous System					Multiple Myeloma				
Male	5	2.0	247.6	(79.8-577.9)	Male	1	1.2	nc	(nc-nc)



Breast	Female	2	1.6	nc	(nc-nc)
	Male	0	0.3	nc	(nc-nc)
Cervix Uteri	Female	47	35.8	131.4	(96.5-174.7)
	Male				
Colon / Rectum	Female	1	2.0	nc	(nc-nc)
	Male	12	12.8	94.1	(48.5-164.3)
Esophagus	Female	14	11.3	123.6	(67.5-207.4)
	Male	2	2.1	nc	(nc-nc)
Hodgkin Lymphoma	Female	1	0.6	nc	(nc-nc)
	Male	2	1.0	nc	(nc-nc)
Kidney & Renal Pelvis	Female	0	0.8	nc	(nc-nc)
	Male	7	3.7	188.6	(75.6-388.7)
Larynx	Female	2	2.2	nc	(nc-nc)
	Male	1	1.6	nc	(nc-nc)
Leukemia	Female	0	0.4	nc	(nc-nc)
	Male	2	2.9	nc	(nc-nc)
Liver and Intrahepatic Bile Ducts	Female	1	2.3	nc	(nc-nc)
	Male	2	1.7	nc	(nc-nc)
Lung and Bronchus	Female	0	0.6	nc	(nc-nc)
	Male				

Non-Hodgkin Lymphoma	Female	0	0.9	nc	(nc-nc)
	Male	3	4.7	nc	(nc-nc)
Oral Cavity & Pharynx	Female	3	3.8	nc	(nc-nc)
	Male	3	3.8	nc	(nc-nc)
Ovary	Female	2	1.6	nc	(nc-nc)
	Male				
Pancreas	Female	3	3.6	nc	(nc-nc)
	Male	1	2.4	nc	(nc-nc)
Prostate	Female	3	2.3	nc	(nc-nc)
	Male	38	34.5	110.2	(78.0-151.3)
Stomach	Female	1	1.2	nc	(nc-nc)
	Male	2	2.2	nc	(nc-nc)
Testis	Female				
	Male	2	1.8	nc	(nc-nc)
Thyroid	Female	5	3.7	135.9	(43.8-317.1)
	Male	1	1.1	nc	(nc-nc)
Uteri Corpus and Uterus, NOS	Female	14	6.6	211.4	(115.5-354.7)
	Male				
All Sites / Types					

Male	17	16.1	105.8	(61.6-169.3)
Female	9	12.8	70.2	(32.0-133.3)

Male	120	116.4	103.1	(85.5-123.3)
Female	123	108.4	113.5	(94.3-135.4)

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ( (Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- Shading indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

66  
Chatham

Observed and Expected Case Counts, with Standardized Incidence Ratios, 1998-2002

	Obs	Exp	SIR	95% CI		Obs	Exp	SIR	95% CI
Bladder, Urinary					Melanoma of Skin				
Male	20	16.9	118.6	(72.4-183.1)	Male	17	6.8	250.4	(145.8-401.0)
Female	13	5.9	220.4	(117.2-376.9)	Female	8	4.6	175.8	(75.7-346.4)
Brain and Other Nervous System					Multiple Myeloma				
Male	4	2.2	nc	(nc-nc)	Male	1	2.2	nc	(nc-nc)
Female	1	1.9	nc	(nc-nc)	Female	0	1.8	nc	(nc-nc)
Breast					Non-Hodgkin Lymphoma				
Male	2	0.4	nc	(nc-nc)	Male	6	7.0	85.2	(31.1-185.4)
Female	73	48.4	151.0	(118.3-189.8)	Female	8	6.6	120.5	(51.9-237.4)
Cervix Uteri					Oral Cavity & Pharynx				
Female	2	1.7	nc	(nc-nc)	Male	7	4.9	144.1	(57.7-296.9)
Colon / Rectum					Female	3	2.5	nc	(nc-nc)
Male	17	25.2	67.5	(39.3-108.1)	Ovary				
Female	30	24.9	120.7	(81.4-172.3)	Female	8	5.1	156.4	(67.3-308.1)
Esophagus					Pancreas				
Male	5	3.6	137.9	(44.4-321.8)	Male	6	4.6	130.4	(47.6-283.9)
Female	1	1.2	nc	(nc-nc)	Female	5	5.2	95.6	(30.8-223.0)

Hodgkin Lymphoma					Prostate				
Male	0	0.7	nc	(nc-nc)	Male	79	61.3	128.8	(102.0-160.5)
Female	1	0.6	nc	(nc-nc)					
Kidney & Renal Pelvis					Stomach				
Male	8	5.5	145.9	(62.8-287.5)	Male	3	4.3	nc	(nc-nc)
Female	6	3.7	161.9	(59.1-352.5)	Female	2	2.7	nc	(nc-nc)
Larynx					Testis				
Male	4	2.6	nc	(nc-nc)	Male	3	0.8	nc	(nc-nc)
Female	0	0.7	nc	(nc-nc)					
Leukemia					Thyroid				
Male	3	4.3	nc	(nc-nc)	Male	1	0.9	nc	(nc-nc)
Female	4	3.6	nc	(nc-nc)	Female	1	2.5	nc	(nc-nc)
Liver and Intrahepatic Bile Ducts					Uteri Corpus and Uterus, NOS				
Male	0	2.6	nc	(nc-nc)					
Female	0	1.1	nc	(nc-nc)	Female	13	9.8	133.0	(70.8-227.5)
Lung and Bronchus					All Sites / Types				
Male	21	31.4	66.9	(41.4-102.2)	Male	221	201.8	109.5	(95.6-125.0)
Female	24	25.7	93.6	(59.9-139.2)	Female	221	174.3	126.8	(110.6-144.7)

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ( (Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- Shading indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

67  
Chelmsford

Observed and Expected Case Counts, with Standardized Incidence Ratios, 1998-2002

	Obs	Exp	SIR	95% CI		Obs	Exp	SIR	95% CI
Bladder, Urinary					Melanoma of Skin				
Male	24	34.4	69.8	(44.7-103.9)	Male	14	18.6	75.3	(41.1-126.3)

Female	19	13.3	142.4	(85.7-222.3)
Brain and Other Nervous System				
Male	8	7.2	110.9	(47.8-218.5)
Female	4	6.1	nc	(nc-nc)
Breast				
Male	1	1.1	nc	(nc-nc)
Female	148	148.8	99.5	(84.1-116.9)
Cervix Uteri				
Female	4	6.9	nc	(nc-nc)
Colon / Rectum				
Male	59	53.8	109.7	(83.5-141.5)
Female	48	53.3	90.1	(66.4-119.4)
Esophagus				
Male	7	8.9	78.8	(31.6-162.4)
Female	3	2.6	nc	(nc-nc)
Hodgkin Lymphoma				
Male	0	3.1	nc	(nc-nc)
Female	3	2.6	nc	(nc-nc)
Kidney & Renal Pelvis				
Male	21	14.8	142.1	(87.9-217.2)
Female	9	9.8	91.4	(41.7-173.5)
Larynx				
Male	5	6.7	74.5	(24.0-173.8)
Female	1	1.8	nc	(nc-nc)
Leukemia				
Male	9	10.9	82.5	(37.6-156.6)
Female	9	9.3	96.8	(44.2-183.7)
Liver and Intrahepatic Bile Ducts				

Female	6	15.5	38.6	(14.1-84.1)
Multiple Myeloma				
Male	3	4.9	nc	(nc-nc)
Female	3	4.2	nc	(nc-nc)
Non-Hodgkin Lymphoma				
Male	21	18.0	116.4	(72.0-177.9)
Female	25	16.8	148.8	(96.3-219.7)
Oral Cavity & Pharynx				
Male	10	14.5	69.1	(33.1-127.0)
Female	7	7.0	99.3	(39.8-204.6)
Ovary				
Female	14	15.0	93.4	(51.0-156.7)
Pancreas				
Male	9	10.1	89.2	(40.7-169.4)
Female	14	11.0	126.9	(69.3-212.9)
Prostate				
Male	168	152.7	110.0	(94.0-127.9)
Stomach				
Male	4	9.1	nc	(nc-nc)
Female	4	5.6	nc	(nc-nc)
Testis				
Male	5	5.4	92.8	(29.9-216.6)
Thyroid				
Male	7	3.7	187.0	(74.9-385.2)
Female	18	11.9	150.8	(89.3-238.3)
Uteri Corpus and Uterus, NOS				

Male	12	6.8	176.0	(90.8-307.5)					
Female	2	2.6	nc	(nc-nc)	Female	29	29.8	97.4	(65.2-139.8)
Lung and Bronchus					All Sites / Types				
Male	70	69.7	100.4	(78.3-126.9)	Male	484	484.7	99.9	(91.2-109.2)
Female	54	63.1	85.6	(64.3-111.7)	Female	453	469.9	96.4	(87.7-105.7)

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ( (Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- Shading indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

68 Chelsea Observed and Expected Case Counts, with Standardized Incidence Ratios, 1998-2002									
	Obs	Exp	SIR	95% CI		Obs	Exp	SIR	95% CI
Bladder, Urinary					Melanoma of Skin				
Male	29	29.7	97.6	(65.4-140.2)	Male	5	15.3	32.8	(10.6-76.4)
Female	10	10.5	95.5	(45.7-175.7)	Female	7	12.2	57.3	(23.0-118.0)
Brain and Other Nervous System					Multiple Myeloma				
Male	8	6.2	129.7	(55.9-255.6)	Male	10	4.1	244.5	(117.1-449.8)
Female	9	5.0	178.4	(81.4-338.8)	Female	1	3.3	nc	(nc-nc)
Breast					Non-Hodgkin Lymphoma				
Male	0	0.9	nc	(nc-nc)	Male	17	15.3	111.3	(64.8-178.2)
Female	77	105.6	72.9	(57.5-91.1)	Female	13	13.3	97.7	(52.0-167.1)
Cervix Uteri					Oral Cavity & Pharynx				
Female	13	5.4	239.8	(127.5-410.0)	Male	15	10.7	139.6	(78.1-230.2)
					Female	2	5.3	nc	(nc-nc)
Colon / Rectum					Ovary				
Male	42	45.6	92.1	(66.4-124.5)					
Female	51	43.3	117.8	(87.7-154.9)	Female	12	11.1	108.6	(56.0-189.6)

Esophagus					Pancreas				
Male	17	6.9	244.8	(142.5-392.0)	Male	13	8.4	154.8	(82.3-264.7)
Female	3	2.1	nc	(nc-nc)	Female	9	9.0	100.2	(45.7-190.3)
Hodgkin Lymphoma					Prostate				
Male	3	3.1	nc	(nc-nc)	Male	79	115.5	68.4	(54.1-85.2)
Female	1	2.6	nc	(nc-nc)					
Kidney & Renal Pelvis					Stomach				
Male	18	11.5	157.0	(93.0-248.1)	Male	13	7.8	165.9	(88.3-283.7)
Female	9	7.4	121.9	(55.6-231.4)	Female	4	4.7	nc	(nc-nc)
Larynx					Testis				
Male	14	5.1	274.7	(150.0-460.9)	Male	2	5.9	nc	(nc-nc)
Female	1	1.3	nc	(nc-nc)					
Leukemia					Thyroid				
Male	5	9.6	51.8	(16.7-120.9)	Male	2	3.1	nc	(nc-nc)
Female	8	7.9	101.7	(43.8-200.4)	Female	9	9.9	91.1	(41.5-172.9)
Liver and Intrahepatic Bile Ducts					Uteri Corpus and Uterus, NOS				
Male	7	5.3	131.9	(52.8-271.7)					
Female	3	2.1	nc	(nc-nc)	Female	20	20.5	97.8	(59.7-151.0)
Lung and Bronchus					All Sites / Types				
Male	75	57.0	131.5	(103.5-164.9)	Male	404	394.0	102.6	(92.8-113.1)
Female	44	47.0	93.6	(68.0-125.7)	Female	341	356.1	95.8	(85.9-106.5)

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ( (Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- Shading indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;



Male	4	1.3	nc	(nc-nc)
Female	0	0.9	nc	(nc-nc)
Liver and Intrahepatic Bile Ducts				
Male	1	0.8	nc	(nc-nc)
Female	0	0.3	nc	(nc-nc)
Lung and Bronchus				
Male	9	8.8	101.7	(46.4-193.1)
Female	11	6.3	173.4	(86.4-310.2)

Male	0	0.4	nc	(nc-nc)
Female	1	1.2	nc	(nc-nc)
Uteri Corpus and Uterus, NOS				
Female	2	3.0	nc	(nc-nc)
All Sites / Types				
Male	56	60.4	92.7	(70.0-120.3)
Female	46	47.1	97.6	(71.4-130.1)

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ( (Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- Shading indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

70  
Chester

Observed and Expected Case Counts, with Standardized Incidence Ratios, 1998-2002

	Obs	Exp	SIR	95% CI
Bladder, Urinary				
Male	2	1.4	nc	(nc-nc)
Female	2	0.4	nc	(nc-nc)
Brain and Other Nervous System				
Male	0	0.3	nc	(nc-nc)
Female	0	0.2	nc	(nc-nc)
Breast				
Male	0	0.0	nc	(nc-nc)
Female	10	5.2	192.2	(92.0-353.5)
Cervix Uteri				
Female	0	0.3	nc	(nc-nc)

	Obs	Exp	SIR	95% CI
Melanoma of Skin				
Male	0	0.8	nc	(nc-nc)
Female	0	0.5	nc	(nc-nc)
Multiple Myeloma				
Male	0	0.2	nc	(nc-nc)
Female	0	0.1	nc	(nc-nc)
Non-Hodgkin Lymphoma				
Male	2	0.7	nc	(nc-nc)
Female	1	0.6	nc	(nc-nc)
Oral Cavity & Pharynx				
Male	0	0.6	nc	(nc-nc)
Female	0	0.2	nc	(nc-nc)



Colon / Rectum						Ovary				
Male	2	2.2	nc	(nc-nc)						
Female	1	1.8	nc	(nc-nc)		Female	2	0.5	nc	(nc-nc)
Esophagus						Pancreas				
Male	0	0.4	nc	(nc-nc)		Male	0	0.4	nc	(nc-nc)
Female	0	0.1	nc	(nc-nc)		Female	0	0.4	nc	(nc-nc)
Hodgkin Lymphoma						Prostate				
Male	0	0.1	nc	(nc-nc)		Male	9	6.1	148.5	(67.8-281.9)
Female	0	0.1	nc	(nc-nc)						
Kidney & Renal Pelvis						Stomach				
Male	0	0.6	nc	(nc-nc)		Male	1	0.4	nc	(nc-nc)
Female	0	0.3	nc	(nc-nc)		Female	0	0.2	nc	(nc-nc)
Larynx						Testis				
Male	0	0.3	nc	(nc-nc)		Male	1	0.2	nc	(nc-nc)
Female	0	0.1	nc	(nc-nc)						
Leukemia						Thyroid				
Male	2	0.5	nc	(nc-nc)		Male	0	0.2	nc	(nc-nc)
Female	0	0.3	nc	(nc-nc)		Female	1	0.4	nc	(nc-nc)
Liver and Intrahepatic Bile Ducts						Uteri Corpus and Uterus, NOS				
Male	0	0.3	nc	(nc-nc)						
Female	0	0.1	nc	(nc-nc)		Female	1	1.0	nc	(nc-nc)
Lung and Bronchus						All Sites / Types				
Male	3	2.8	nc	(nc-nc)		Male	22	19.7	111.9	(70.1-169.4)
Female	2	2.2	nc	(nc-nc)		Female	21	16.1	130.1	(80.5-198.9)

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ( (Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- Shading indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

## Chesterfield

## Observed and Expected Case Counts, with Standardized Incidence Ratios, 1998-2002

	Obs	Exp	SIR	95% CI		Obs	Exp	SIR	95% CI
Bladder, Urinary					Melanoma of Skin				
Male	1	1.2	nc	(nc-nc)	Male	0	0.6	nc	(nc-nc)
Female	0	0.3	nc	(nc-nc)	Female	1	0.5	nc	(nc-nc)
Brain and Other Nervous System					Multiple Myeloma				
Male	0	0.2	nc	(nc-nc)	Male	1	0.2	nc	(nc-nc)
Female	0	0.2	nc	(nc-nc)	Female	1	0.1	nc	(nc-nc)
Breast					Non-Hodgkin Lymphoma				
Male	0	0.0	nc	(nc-nc)	Male	0	0.6	nc	(nc-nc)
Female	5	4.4	113.1	(36.5-264.0)	Female	0	0.5	nc	(nc-nc)
Cervix Uteri					Oral Cavity & Pharynx				
Female	0	0.2	nc	(nc-nc)	Male	0	0.5	nc	(nc-nc)
					Female	0	0.2	nc	(nc-nc)
Colon / Rectum					Ovary				
Male	0	1.8	nc	(nc-nc)					
Female	1	1.3	nc	(nc-nc)	Female	1	0.4	nc	(nc-nc)
Esophagus					Pancreas				
Male	0	0.3	nc	(nc-nc)	Male	0	0.3	nc	(nc-nc)
Female	0	0.1	nc	(nc-nc)	Female	0	0.3	nc	(nc-nc)
Hodgkin Lymphoma					Prostate				
Male	0	0.1	nc	(nc-nc)	Male	5	4.9	101.8	(32.8-237.5)
Female	0	0.1	nc	(nc-nc)					
Kidney & Renal Pelvis					Stomach				
Male	0	0.5	nc	(nc-nc)	Male	0	0.3	nc	(nc-nc)
Female	1	0.3	nc	(nc-nc)	Female	0	0.1	nc	(nc-nc)
Larynx					Testis				

Male	0	0.2	nc	(nc-nc)	Male	1	0.2	nc	(nc-nc)
Female	0	0.0	nc	(nc-nc)					
Leukemia					Thyroid				
Male	0	0.4	nc	(nc-nc)	Male	0	0.1	nc	(nc-nc)
Female	0	0.3	nc	(nc-nc)	Female	0	0.4	nc	(nc-nc)
Liver and Intrahepatic Bile Ducts					Uteri Corpus and Uterus, NOS				
Male	0	0.2	nc	(nc-nc)					
Female	0	0.1	nc	(nc-nc)	Female	0	0.9	nc	(nc-nc)
Lung and Bronchus					All Sites / Types				
Male	1	2.3	nc	(nc-nc)	Male	11	16.2	68.1	(33.9-121.8)
Female	2	1.6	nc	(nc-nc)	Female	12	13.1	91.6	(47.3-160.0)

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ( (Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- Shading indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

72  
Chicopee

Observed and Expected Case Counts, with Standardized Incidence Ratios, 1998-2002

	Obs	Exp	SIR	95% CI		Obs	Exp	SIR	95% CI
Bladder, Urinary					Melanoma of Skin				
Male	70	67.8	103.3	(80.5-130.5)	Male	38	32.4	117.3	(83.0-161.0)
Female	30	27.0	111.1	(74.9-158.6)	Female	19	26.5	71.7	(43.1-112.0)
Brain and Other Nervous System					Multiple Myeloma				
Male	14	11.9	117.3	(64.1-196.9)	Male	7	9.3	75.5	(30.3-155.6)
Female	16	10.9	146.9	(83.9-238.5)	Female	9	8.5	106.2	(48.5-201.6)
Breast					Non-Hodgkin Lymphoma				
Male	2	2.0	nc	(nc-nc)	Male	29	32.5	89.3	(59.8-128.3)
Female	244	256.8	95.0	(83.5-107.7)	Female	23	32.8	70.2	(44.5-105.3)

Cervix Uteri						Oral Cavity & Pharynx					
	Female	9	11.2	80.7	(36.8-153.1)		Male	24	23.7	101.1	(64.8-150.5)
							Female	12	12.8	93.7	(48.4-163.7)
Colon / Rectum						Ovary					
	Male	101	103.4	97.7	(79.6-118.7)						
	Female	116	111.1	104.4	(86.3-125.2)		Female	32	26.6	120.2	(82.2-169.6)
Esophagus						Pancreas					
	Male	19	15.8	120.2	(72.3-187.7)		Male	13	19.1	68.1	(36.2-116.4)
	Female	7	5.4	129.0	(51.7-265.8)		Female	20	23.2	86.1	(52.6-133.1)
Hodgkin Lymphoma						Prostate					
	Male	2	5.0	nc	(nc-nc)		Male	274	267.0	102.6	(90.8-115.5)
	Female	4	4.5	nc	(nc-nc)						
Kidney & Renal Pelvis						Stomach					
	Male	22	25.5	86.1	(54.0-130.4)		Male	22	17.5	125.9	(78.9-190.6)
	Female	13	18.5	70.2	(37.3-120.0)		Female	15	11.7	128.2	(71.7-211.5)
Larynx						Testis					
	Male	12	11.6	103.3	(53.3-180.4)		Male	8	8.2	97.1	(41.8-191.3)
	Female	3	3.3	nc	(nc-nc)						
Leukemia						Thyroid					
	Male	21	20.0	105.0	(65.0-160.6)		Male	3	5.7	nc	(nc-nc)
	Female	10	17.9	56.0	(26.8-103.0)		Female	10	18.6	53.8	(25.8-99.0)
Liver and Intrahepatic Bile Ducts						Uteri Corpus and Uterus, NOS					
	Male	13	11.9	109.6	(58.3-187.5)						
	Female	4	5.2	nc	(nc-nc)		Female	56	51.0	109.9	(83.0-142.7)
Lung and Bronchus						All Sites / Types					
	Male	121	131.8	91.8	(76.2-109.7)		Male	875	879.8	99.5	(93.0-106.3)
	Female	110	123.6	89.0	(73.1-107.2)		Female	843	872.7	96.6	(90.2-103.3)

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ( (Obs / Exp) X 100);

- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- Shading indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

73  
Chilmark

Observed and Expected Case Counts, with Standardized Incidence Ratios, 1998-2002

	Obs	Exp	SIR	95% CI		Obs	Exp	SIR	95% CI
Bladder, Urinary					Melanoma of Skin				
Male	1	1.3	nc	(nc-nc)	Male	0	0.6	nc	(nc-nc)
Female	0	0.4	nc	(nc-nc)	Female	2	0.4	nc	(nc-nc)
Brain and Other Nervous System					Multiple Myeloma				
Male	0	0.2	nc	(nc-nc)	Male	0	0.2	nc	(nc-nc)
Female	1	0.2	nc	(nc-nc)	Female	0	0.1	nc	(nc-nc)
Breast					Non-Hodgkin Lymphoma				
Male	0	0.0	nc	(nc-nc)	Male	0	0.6	nc	(nc-nc)
Female	9	4.1	220.1	(100.4-417.8)	Female	1	0.5	nc	(nc-nc)
Cervix Uteri					Oral Cavity & Pharynx				
Female	0	0.2	nc	(nc-nc)	Male	1	0.5	nc	(nc-nc)
					Female	0	0.2	nc	(nc-nc)
Colon / Rectum					Ovary				
Male	1	2.0	nc	(nc-nc)					
Female	2	1.6	nc	(nc-nc)	Female	0	0.4	nc	(nc-nc)
Esophagus					Pancreas				
Male	0	0.3	nc	(nc-nc)	Male	0	0.4	nc	(nc-nc)
Female	1	0.1	nc	(nc-nc)	Female	0	0.3	nc	(nc-nc)
Hodgkin Lymphoma					Prostate				
Male	0	0.1	nc	(nc-nc)	Male	11	5.1	217.4	(108.4-389.0)
Female	0	0.1	nc	(nc-nc)					
Kidney & Renal Pelvis					Stomach				

Larynx	Male	2	0.5	nc	(nc-nc)	Testis	Male	0	0.3	nc	(nc-nc)
	Female	0	0.3	nc	(nc-nc)		Female	0	0.2	nc	(nc-nc)
Leukemia	Male	0	0.2	nc	(nc-nc)	Thyroid	Male	0	0.1	nc	(nc-nc)
	Female	0	0.0	nc	(nc-nc)		Female	0	0.3	nc	(nc-nc)
Liver and Intrahepatic Bile Ducts	Male	0	0.4	nc	(nc-nc)	Uteri Corpus and Uterus, NOS	Male	0	0.1	nc	(nc-nc)
	Female	0	0.3	nc	(nc-nc)		Female	0	0.3	nc	(nc-nc)
Lung and Bronchus	Male	0	0.2	nc	(nc-nc)	All Sites / Types	Female	0	0.8	nc	(nc-nc)
	Female	0	0.1	nc	(nc-nc)		Male	18	16.5	109.0	(64.6-172.2)
	Male	1	2.5	nc	(nc-nc)		Female	19	13.1	145.3	(87.4-226.9)
	Female	2	1.8	nc	(nc-nc)						

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ( (Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- Shading indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

74

#### Clarksburg

#### Observed and Expected Case Counts, with Standardized Incidence Ratios, 1998-2002

	Obs	Exp	SIR	95% CI		Obs	Exp	SIR	95% CI
Bladder, Urinary					Melanoma of Skin				
Male	3	2.2	nc	(nc-nc)	Male	0	1.1	nc	(nc-nc)
Female	1	0.8	nc	(nc-nc)	Female	1	0.8	nc	(nc-nc)
Brain and Other Nervous System					Multiple Myeloma				
Male	0	0.4	nc	(nc-nc)	Male	0	0.3	nc	(nc-nc)
Female	0	0.3	nc	(nc-nc)	Female	0	0.2	nc	(nc-nc)

Breast						Non-Hodgkin Lymphoma					
Male	0	0.1	nc	(nc-nc)		Male	2	1.1	nc	(nc-nc)	
Female	2	8.2	nc	(nc-nc)		Female	1	1.0	nc	(nc-nc)	
Cervix Uteri						Oral Cavity & Pharynx					
Female	0	0.4	nc	(nc-nc)		Male	1	0.9	nc	(nc-nc)	
						Female	1	0.4	nc	(nc-nc)	
Colon / Rectum						Ovary					
Male	3	3.4	nc	(nc-nc)							
Female	2	3.1	nc	(nc-nc)		Female	0	0.8	nc	(nc-nc)	
Esophagus						Pancreas					
Male	1	0.6	nc	(nc-nc)		Male	0	0.6	nc	(nc-nc)	
Female	0	0.2	nc	(nc-nc)		Female	0	0.6	nc	(nc-nc)	
Hodgkin Lymphoma						Prostate					
Male	2	0.2	nc	(nc-nc)		Male	6	9.9	60.9	(22.2-132.6)	
Female	0	0.1	nc	(nc-nc)							
Kidney & Renal Pelvis						Stomach					
Male	1	0.9	nc	(nc-nc)		Male	0	0.6	nc	(nc-nc)	
Female	0	0.6	nc	(nc-nc)		Female	0	0.3	nc	(nc-nc)	
Larynx						Testis					
Male	0	0.4	nc	(nc-nc)		Male	1	0.3	nc	(nc-nc)	
Female	0	0.1	nc	(nc-nc)							
Leukemia						Thyroid					
Male	1	0.7	nc	(nc-nc)		Male	1	0.2	nc	(nc-nc)	
Female	0	0.5	nc	(nc-nc)		Female	1	0.6	nc	(nc-nc)	
Liver and Intrahepatic Bile Ducts						Uteri Corpus and Uterus, NOS					
Male	0	0.4	nc	(nc-nc)							
Female	0	0.1	nc	(nc-nc)		Female	3	1.7	nc	(nc-nc)	
Lung and Bronchus						All Sites / Types					
Male	7	4.5	155.3	(62.2-319.9)		Male	30	30.6	98.1	(66.2-140.0)	

Female      6      3.7      164.2      (60.0-357.4)

Female      20      26.4      75.8      (46.3-117.1)

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ( (Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- Shading indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

75  
Clinton

Observed and Expected Case Counts, with Standardized Incidence Ratios, 1998-2002

	Obs	Exp	SIR	95% CI		Obs	Exp	SIR	95% CI
Bladder, Urinary					Melanoma of Skin				
Male	15	13.8	108.9	(60.9-179.6)	Male	3	7.0	nc	(nc-nc)
Female	4	5.8	nc	(nc-nc)	Female	5	6.1	81.8	(26.4-190.8)
Brain and Other Nervous System					Multiple Myeloma				
Male	3	2.7	nc	(nc-nc)	Male	2	1.9	nc	(nc-nc)
Female	2	2.5	nc	(nc-nc)	Female	1	1.8	nc	(nc-nc)
Breast					Non-Hodgkin Lymphoma				
Male	0	0.4	nc	(nc-nc)	Male	8	7.0	114.7	(49.4-226.1)
Female	52	56.7	91.8	(68.5-120.3)	Female	3	7.2	nc	(nc-nc)
Cervix Uteri					Oral Cavity & Pharynx				
Female	4	2.7	nc	(nc-nc)	Male	7	5.1	137.1	(54.9-282.5)
Colon / Rectum					Female	0	2.8	nc	(nc-nc)
Male	18	21.2	85.1	(50.4-134.4)	Ovary				
Female	25	24.0	104.3	(67.5-153.9)	Female	9	5.9	153.1	(69.9-290.6)
Esophagus					Pancreas				
Male	6	3.3	183.3	(66.9-399.0)	Male	2	3.9	nc	(nc-nc)
Female	2	1.2	nc	(nc-nc)	Female	7	5.0	140.5	(56.3-289.6)
Hodgkin Lymphoma					Prostate				



Male	4	1.2	nc	(nc-nc)	Male	48	54.8	87.6	(64.6-116.1)
Female	1	1.1	nc	(nc-nc)					
Kidney & Renal Pelvis					Stomach				
Male	3	5.4	nc	(nc-nc)	Male	4	3.6	nc	(nc-nc)
Female	5	4.0	125.1	(40.3-291.9)	Female	0	2.6	nc	(nc-nc)
Larynx					Testis				
Male	6	2.4	247.3	(90.3-538.2)	Male	0	2.3	nc	(nc-nc)
Female	0	0.7	nc	(nc-nc)					
Leukemia					Thyroid				
Male	1	4.3	nc	(nc-nc)	Male	1	1.4	nc	(nc-nc)
Female	3	4.0	nc	(nc-nc)	Female	2	4.6	nc	(nc-nc)
Liver and Intrahepatic Bile Ducts					Uteri Corpus and Uterus, NOS				
Male	3	2.5	nc	(nc-nc)					
Female	1	1.1	nc	(nc-nc)	Female	5	11.0	45.3	(14.6-105.7)
Lung and Bronchus					All Sites / Types				
Male	32	26.9	119.1	(81.5-168.2)	Male	174	183.2	95.0	(81.4-110.2)
Female	25	26.2	95.3	(61.7-140.7)	Female	176	191.2	92.1	(79.0-106.7)

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ( (Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- Shading indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

76  
Cohasset

Observed and Expected Case Counts, with Standardized Incidence Ratios, 1998-2002

	Obs	Exp	SIR	95% CI		Obs	Exp	SIR	95% CI
Bladder, Urinary					Melanoma of Skin				
Male	10	8.7	115.6	(55.3-212.6)	Male	4	4.4	nc	(nc-nc)
Female	2	3.3	nc	(nc-nc)	Female	13	3.5	372.1	(197.9-636.4)

Brain and Other Nervous System						Multiple Myeloma				
Male	4	1.7	nc	(nc-nc)		Male	2	1.2	nc	(nc-nc)
Female	0	1.4	nc	(nc-nc)		Female	0	1.0	nc	(nc-nc)
Breast						Non-Hodgkin Lymphoma				
Male	1	0.3	nc	(nc-nc)		Male	4	4.3	nc	(nc-nc)
Female	41	34.6	118.5	(85.0-160.8)		Female	4	4.0	nc	(nc-nc)
Cervix Uteri						Oral Cavity & Pharynx				
						Male	7	3.5	202.6	(81.2-417.4)
Female	3	1.5	nc	(nc-nc)		Female	2	1.7	nc	(nc-nc)
Colon / Rectum						Ovary				
Male	19	13.4	141.5	(85.1-221.0)						
Female	15	13.1	114.3	(63.9-188.5)		Female	3	3.5	nc	(nc-nc)
Esophagus						Pancreas				
Male	2	2.2	nc	(nc-nc)		Male	2	2.5	nc	(nc-nc)
Female	0	0.6	nc	(nc-nc)		Female	0	2.7	nc	(nc-nc)
Hodgkin Lymphoma						Prostate				
Male	0	0.6	nc	(nc-nc)		Male	41	37.0	110.8	(79.5-150.3)
Female	1	0.5	nc	(nc-nc)						
Kidney & Renal Pelvis						Stomach				
Male	3	3.6	nc	(nc-nc)		Male	1	2.3	nc	(nc-nc)
Female	1	2.3	nc	(nc-nc)		Female	0	1.4	nc	(nc-nc)
Larynx						Testis				
Male	1	1.6	nc	(nc-nc)		Male	1	1.0	nc	(nc-nc)
Female	1	0.4	nc	(nc-nc)						
Leukemia						Thyroid				
Male	4	2.6	nc	(nc-nc)		Male	3	0.8	nc	(nc-nc)
Female	2	2.2	nc	(nc-nc)		Female	0	2.5	nc	(nc-nc)
Liver and Intrahepatic Bile Ducts						Uteri Corpus and Uterus, NOS				
Male	2	1.7	nc	(nc-nc)						

Female	2	0.6	nc	(nc-nc)	Female	3	6.9	nc	(nc-nc)
Lung and Bronchus					All Sites / Types				
Male	13	17.3	75.2	(40.0-128.6)	Male	130	118.0	110.1	(92.0-130.8)
Female	11	15.2	72.6	(36.2-129.9)	Female	113	111.1	101.7	(83.9-122.3)

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ( (Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- Shading indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

77  
Colrain

Observed and Expected Case Counts, with Standardized Incidence Ratios, 1998-2002

	Obs	Exp	SIR	95% CI		Obs	Exp	SIR	95% CI
Bladder, Urinary					Melanoma of Skin				
Male	1	2.0	nc	(nc-nc)	Male	0	1.0	nc	(nc-nc)
Female	0	0.6	nc	(nc-nc)	Female	0	0.7	nc	(nc-nc)
Brain and Other Nervous System					Multiple Myeloma				
Male	1	0.4	nc	(nc-nc)	Male	1	0.3	nc	(nc-nc)
Female	0	0.3	nc	(nc-nc)	Female	1	0.2	nc	(nc-nc)
Breast					Non-Hodgkin Lymphoma				
Male	0	0.1	nc	(nc-nc)	Male	1	1.0	nc	(nc-nc)
Female	9	6.9	131.2	(59.8-249.0)	Female	0	0.8	nc	(nc-nc)
Cervix Uteri					Oral Cavity & Pharynx				
Female	1	0.3	nc	(nc-nc)	Male	0	0.8	nc	(nc-nc)
Colon / Rectum					Female	1	0.3	nc	(nc-nc)
Male	4	3.1	nc	(nc-nc)	Ovary				
Female	4	2.3	nc	(nc-nc)	Female	1	0.7	nc	(nc-nc)
Esophagus					Pancreas				

Hodgkin Lymphoma	Male	0	0.5	nc	(nc-nc)	Prostate	Male	1	0.6	nc	(nc-nc)
	Female	0	0.1	nc	(nc-nc)		Female	2	0.5	nc	(nc-nc)
Kidney & Renal Pelvis	Male	0	0.2	nc	(nc-nc)	Stomach	Male	4	8.3	nc	(nc-nc)
	Female	0	0.1	nc	(nc-nc)		Male	0	0.5	nc	(nc-nc)
Larynx	Male	1	0.4	nc	(nc-nc)	Testis	Female	0	0.2	nc	(nc-nc)
	Female	0	0.1	nc	(nc-nc)		Male	0	0.3	nc	(nc-nc)
Leukemia	Male	1	0.6	nc	(nc-nc)	Thyroid	Male	0	0.2	nc	(nc-nc)
	Female	1	0.4	nc	(nc-nc)		Female	0	0.6	nc	(nc-nc)
Liver and Intrahepatic Bile Ducts	Male	0	0.4	nc	(nc-nc)	Uteri Corpus and Uterus, NOS					
	Female	0	0.1	nc	(nc-nc)		Female	1	1.3	nc	(nc-nc)
Lung and Bronchus	Male	4	4.0	nc	(nc-nc)	All Sites / Types	Male	20	27.3	73.3	(44.8-113.2)
	Female	4	2.8	nc	(nc-nc)		Female	27	21.3	126.9	(83.6-184.6)

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ( (Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- Shading indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Bladder, Urinary						Melanoma of Skin				
Male	17	23.1	73.6	(42.9-117.9)		Male	24	11.7	205.1	(131.3-305.1)
Female	10	7.8	127.9	(61.2-235.2)		Female	15	8.2	183.7	(102.7-303.0)
Brain and Other Nervous System						Multiple Myeloma				
Male	4	4.3	nc	(nc-nc)		Male	5	3.2	154.2	(49.7-360.0)
Female	5	3.3	150.3	(48.4-350.7)		Female	2	2.4	nc	(nc-nc)
Breast						Non-Hodgkin Lymphoma				
Male	0	0.7	nc	(nc-nc)		Male	14	11.5	121.7	(66.5-204.2)
Female	108	82.8	130.5	(107.1-157.6)		Female	13	9.5	136.8	(72.7-233.9)
Cervix Uteri						Oral Cavity & Pharynx				
Female	3	3.5	nc	(nc-nc)		Male	8	9.0	88.9	(38.3-175.2)
Colon / Rectum						Female	6	4.0	151.6	(55.4-329.9)
Male	26	35.7	72.8	(47.5-106.7)		Ovary				
Female	31	31.6	98.1	(66.6-139.2)		Female	4	8.4	nc	(nc-nc)
Esophagus						Pancreas				
Male	4	5.7	nc	(nc-nc)		Male	5	6.7	75.1	(24.2-175.1)
Female	1	1.6	nc	(nc-nc)		Female	8	6.6	121.7	(52.4-239.7)
Hodgkin Lymphoma						Prostate				
Male	2	1.8	nc	(nc-nc)		Male	97	97.0	100.0	(81.1-122.0)
Female	1	1.2	nc	(nc-nc)		Stomach				
Kidney & Renal Pelvis						Male	3	6.0	nc	(nc-nc)
Male	5	9.3	53.7	(17.3-125.4)		Female	3	3.3	nc	(nc-nc)
Female	7	5.6	125.3	(50.2-258.2)		Testis				
Larynx						Male	6	2.9	207.5	(75.8-451.6)
Male	2	4.2	nc	(nc-nc)		Thyroid				
Female	2	1.0	nc	(nc-nc)		Male	3	2.2	nc	(nc-nc)
Leukemia										
Male	5	6.9	72.3	(23.3-168.7)						

Liver and Intrahepatic Bile Ducts	Female	5	5.3	95.0	(30.6-221.8)
	Male	3	4.3	nc	(nc-nc)
Lung and Bronchus	Female	3	1.5	nc	(nc-nc)
	Male	22	45.7	48.1	(30.1-72.8)
	Female	24	36.2	66.2	(42.4-98.6)

Uteri Corpus and Uterus, NOS	Female	5	5.8	86.9	(28.0-202.8)
All Sites / Types	Female	19	16.6	114.4	(68.8-178.6)
	Male	264	311.9	84.7	(74.7-95.5)
	Female	287	265.2	108.2	(96.1-121.5)

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ( (Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- Shading indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

79

Conway

Observed and Expected Case Counts, with Standardized Incidence Ratios, 1998-2002

	Obs	Exp	SIR	95% CI
Bladder, Urinary				
Male	0	1.7	nc	(nc-nc)
Female	0	0.6	nc	(nc-nc)
Brain and Other Nervous System				
Male	0	0.4	nc	(nc-nc)
Female	0	0.3	nc	(nc-nc)
Breast				
Male	0	0.1	nc	(nc-nc)
Female	7	7.2	96.8	(38.8-199.4)
Cervix Uteri				
Female	1	0.4	nc	(nc-nc)
Colon / Rectum				

	Obs	Exp	SIR	95% CI
Melanoma of Skin				
Male	1	1.0	nc	(nc-nc)
Female	1	0.8	nc	(nc-nc)
Multiple Myeloma				
Male	0	0.3	nc	(nc-nc)
Female	0	0.2	nc	(nc-nc)
Non-Hodgkin Lymphoma				
Male	1	0.9	nc	(nc-nc)
Female	0	0.7	nc	(nc-nc)
Oral Cavity & Pharynx				
Male	1	0.8	nc	(nc-nc)
Female	1	0.3	nc	(nc-nc)
Ovary				

Esophagus	Male	2	2.7	nc	(nc-nc)	Pancreas	Female	0	0.7	nc	(nc-nc)
	Female	2	2.2	nc	(nc-nc)						
Hodgkin Lymphoma	Male	0	0.5	nc	(nc-nc)	Prostate	Male	0	0.5	nc	(nc-nc)
	Female	0	0.1	nc	(nc-nc)		Female	0	0.4	nc	(nc-nc)
Kidney & Renal Pelvis	Male	0	0.2	nc	(nc-nc)	Stomach	Male	9	7.4	121.1	(55.3-230.0)
	Female	0	0.1	nc	(nc-nc)		Female	0	0.2	nc	(nc-nc)
Larynx	Male	1	0.8	nc	(nc-nc)	Testis	Male	0	0.5	nc	(nc-nc)
	Female	0	0.4	nc	(nc-nc)		Female	0	0.2	nc	(nc-nc)
Leukemia	Male	1	0.3	nc	(nc-nc)	Thyroid	Male	0	0.3	nc	(nc-nc)
	Female	0	0.1	nc	(nc-nc)		Female	0	0.6	nc	(nc-nc)
Liver and Intrahepatic Bile Ducts	Male	0	0.6	nc	(nc-nc)	Uteri Corpus and Uterus, NOS	Male	0	0.2	nc	(nc-nc)
	Female	1	0.4	nc	(nc-nc)		Female	0	0.6	nc	(nc-nc)
Lung and Bronchus	Male	0	0.4	nc	(nc-nc)	All Sites / Types	Female	0	1.4	nc	(nc-nc)
	Female	0	0.1	nc	(nc-nc)		Male	19	24.2	78.6	(47.3-122.7)
	Male	0	3.4	nc	(nc-nc)		Female	18	21.4	84.1	(49.8-133.0)
	Female	3	2.6	nc	(nc-nc)						

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ( (Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- Shading indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

80  
Cummington

Observed and Expected Case Counts, with Standardized Incidence Ratios, 1998-2002

	Obs	Exp	SIR	95% CI		Obs	Exp	SIR	95% CI
Bladder, Urinary					Melanoma of Skin				
Male	1	0.9	nc	(nc-nc)	Male	0	0.5	nc	(nc-nc)
Female	0	0.3	nc	(nc-nc)	Female	0	0.4	nc	(nc-nc)
Brain and Other Nervous System					Multiple Myeloma				
Male	0	0.2	nc	(nc-nc)	Male	0	0.1	nc	(nc-nc)
Female	1	0.2	nc	(nc-nc)	Female	1	0.1	nc	(nc-nc)
Breast					Non-Hodgkin Lymphoma				
Male	0	0.0	nc	(nc-nc)	Male	1	0.5	nc	(nc-nc)
Female	4	3.7	nc	(nc-nc)	Female	0	0.4	nc	(nc-nc)
Cervix Uteri					Oral Cavity & Pharynx				
Female	0	0.2	nc	(nc-nc)	Male	0	0.4	nc	(nc-nc)
					Female	1	0.2	nc	(nc-nc)
Colon / Rectum					Ovary				
Male	1	1.5	nc	(nc-nc)					
Female	2	1.3	nc	(nc-nc)	Female	1	0.4	nc	(nc-nc)
Esophagus					Pancreas				
Male	0	0.2	nc	(nc-nc)	Male	0	0.3	nc	(nc-nc)
Female	0	0.1	nc	(nc-nc)	Female	0	0.3	nc	(nc-nc)
Hodgkin Lymphoma					Prostate				
Male	0	0.1	nc	(nc-nc)	Male	2	4.0	nc	(nc-nc)
Female	1	0.1	nc	(nc-nc)					
Kidney & Renal Pelvis					Stomach				
Male	1	0.4	nc	(nc-nc)	Male	0	0.2	nc	(nc-nc)
Female	0	0.2	nc	(nc-nc)	Female	0	0.1	nc	(nc-nc)
Larynx					Testis				
Male	0	0.2	nc	(nc-nc)	Male	0	0.2	nc	(nc-nc)



Leukemia	Female	0	0.0	nc	(nc-nc)
	Male	1	0.3	nc	(nc-nc)
	Female	0	0.2	nc	(nc-nc)
Liver and Intrahepatic Bile Ducts	Male	0	0.2	nc	(nc-nc)
	Female	0	0.1	nc	(nc-nc)
Lung and Bronchus	Male	1	1.9	nc	(nc-nc)
	Female	1	1.5	nc	(nc-nc)

#### Thyroid

Male	0	0.1	nc	(nc-nc)
Female	0	0.3	nc	(nc-nc)

#### Uteri Corpus and Uterus, NOS

Female	1	0.7	nc	(nc-nc)
--------	---	-----	----	---------

#### All Sites / Types

Male	8	13.0	61.3	(26.4-120.9)
Female	13	11.6	111.9	(59.5-191.3)

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ( (Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- Shading indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

81

#### Dalton

#### Observed and Expected Case Counts, with Standardized Incidence Ratios, 1998-2002

	Obs	Exp	SIR	95% CI		Obs	Exp	SIR	95% CI
Bladder, Urinary					Melanoma of Skin				
Male	10	8.0	124.4	(59.6-228.8)	Male	5	4.0	124.5	(40.1-290.6)
Female	3	3.2	nc	(nc-nc)	Female	2	3.3	nc	(nc-nc)
Brain and Other Nervous System					Multiple Myeloma				
Male	1	1.5	nc	(nc-nc)	Male	1	1.1	nc	(nc-nc)
Female	1	1.3	nc	(nc-nc)	Female	1	1.0	nc	(nc-nc)
Breast					Non-Hodgkin Lymphoma				
Male	1	0.2	nc	(nc-nc)	Male	5	4.0	125.5	(40.4-292.9)
Female	35	32.6	107.4	(74.8-149.4)	Female	4	3.9	nc	(nc-nc)
Cervix Uteri					Oral Cavity & Pharynx				

Colon / Rectum	Male	0	3.0	nc	(nc-nc)	Ovary	Male	0	3.0	nc	(nc-nc)
	Female	0	1.6	nc	(nc-nc)		Female	0	1.6	nc	(nc-nc)
	Male	14	12.4	113.1	(61.8-189.7)		Female	3	3.3	nc	(nc-nc)
Esophagus	Female	17	13.2	128.9	(75.1-206.4)	Pancreas	Female	3	3.3	nc	(nc-nc)
	Male	0	1.9	nc	(nc-nc)		Male	2	2.3	nc	(nc-nc)
Hodgkin Lymphoma	Female	0	0.6	nc	(nc-nc)	Prostate	Female	2	2.7	nc	(nc-nc)
	Male	0	0.6	nc	(nc-nc)		Male	38	32.7	116.3	(82.3-159.7)
	Female	1	0.5	nc	(nc-nc)		Male	2	2.1	nc	(nc-nc)
Kidney & Renal Pelvis	Male	5	3.2	157.6	(50.8-367.8)	Stomach	Female	0	1.4	nc	(nc-nc)
	Female	5	2.3	221.5	(71.4-516.8)		Male	1	1.0	nc	(nc-nc)
Larynx	Male	1	1.4	nc	(nc-nc)	Testis	Male	1	1.0	nc	(nc-nc)
	Female	0	0.4	nc	(nc-nc)		Female	2	2.4	nc	(nc-nc)
Leukemia	Male	3	2.4	nc	(nc-nc)	Thyroid	Male	0	0.7	nc	(nc-nc)
	Female	1	2.2	nc	(nc-nc)		Female	2	2.4	nc	(nc-nc)
Liver and Intrahepatic Bile Ducts	Male	1	1.5	nc	(nc-nc)	Uteri Corpus and Uterus, NOS	Female	6	6.4	93.5	(34.2-203.6)
	Female	1	0.6	nc	(nc-nc)		Male	114	106.9	106.7	(88.0-128.1)
Lung and Bronchus	Male	19	15.8	120.6	(72.6-188.3)	All Sites / Types	Female	104	107.1	97.1	(79.3-117.7)
	Female	15	14.8	101.6	(56.8-167.5)		Male	114	106.9	106.7	(88.0-128.1)

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ( (Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;

- Shading indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

82

Danvers

Observed and Expected Case Counts, with Standardized Incidence Ratios, 1998-2002

	Obs	Exp	SIR	95% CI		Obs	Exp	SIR	95% CI
Bladder, Urinary					Melanoma of Skin				
Male	40	30.1	132.7	(94.8-180.7)	Male	12	15.0	79.9	(41.3-139.7)
Female	12	11.9	100.5	(51.9-175.6)	Female	11	12.4	88.6	(44.2-158.5)
Brain and Other Nervous System					Multiple Myeloma				
Male	5	5.6	90.0	(29.0-209.9)	Male	4	4.2	nc	(nc-nc)
Female	5	5.0	99.5	(32.1-232.1)	Female	3	3.7	nc	(nc-nc)
Breast					Non-Hodgkin Lymphoma				
Male	1	0.9	nc	(nc-nc)	Male	15	14.8	101.0	(56.5-166.6)
Female	122	120.8	101.0	(83.9-120.6)	Female	15	14.6	102.7	(57.5-169.5)
Cervix Uteri					Oral Cavity & Pharynx				
Female	8	5.4	148.1	(63.8-291.9)	Male	5	11.3	44.2	(14.2-103.2)
Colon / Rectum					Female	5	5.9	85.0	(27.4-198.4)
Male	68	46.4	146.5	(113.8-185.7)	Ovary				
Female	44	48.8	90.2	(65.5-121.0)	Female	13	12.4	105.3	(56.0-180.0)
Esophagus					Pancreas				
Male	8	7.3	109.5	(47.1-215.8)	Male	11	8.6	127.7	(63.6-228.4)
Female	3	2.4	nc	(nc-nc)	Female	11	10.2	108.2	(53.9-193.6)
Hodgkin Lymphoma					Prostate				
Male	1	2.3	nc	(nc-nc)	Male	118	124.3	94.9	(78.6-113.7)
Female	1	2.0	nc	(nc-nc)	Stomach				
Kidney & Renal Pelvis					Male	5	7.8	63.8	(20.6-148.9)
Male	13	11.9	109.3	(58.1-186.9)					

Larynx	Female	6	8.4	71.5	(26.1-155.7)
	Male	0	5.4	nc	(nc-nc)
	Female	0	1.5	nc	(nc-nc)
Leukemia					
	Male	12	9.0	133.3	(68.8-232.8)
	Female	8	8.1	99.2	(42.7-195.5)
Liver and Intrahepatic Bile Ducts					
	Male	7	5.5	126.6	(50.7-260.9)
	Female	1	2.3	nc	(nc-nc)
Lung and Bronchus					
	Male	64	59.5	107.5	(82.8-137.3)
	Female	69	54.7	126.1	(98.1-159.6)

Testis	Female	3	5.2	nc	(nc-nc)
	Male	4	3.8	nc	(nc-nc)
Thyroid					
	Male	1	2.8	nc	(nc-nc)
	Female	7	9.0	77.6	(31.1-159.9)
Uteri Corpus and Uterus, NOS					
	Female	16	23.8	67.2	(38.4-109.1)
All Sites / Types					
	Male	425	402.5	105.6	(95.8-116.1)
	Female	393	397.8	98.8	(89.3-109.0)

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ( (Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- Shading indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

83

#### Dartmouth

#### Observed and Expected Case Counts, with Standardized Incidence Ratios, 1998-2002

	Obs	Exp	SIR	95% CI
Bladder, Urinary				
Male	32	36.2	88.4	(60.5-124.9)
Female	16	13.6	117.8	(67.3-191.2)
Brain and Other Nervous System				
Male	6	6.8	88.8	(32.4-193.2)
Female	7	5.7	122.8	(49.2-253.0)
Breast				

	Obs	Exp	SIR	95% CI
Melanoma of Skin				
Male	13	18.1	71.7	(38.1-122.6)
Female	19	14.1	134.6	(81.0-210.3)
Multiple Myeloma				
Male	6	5.0	118.9	(43.4-258.8)
Female	11	4.3	258.8	(129.0-463.1)
Non-Hodgkin Lymphoma				

Male	1	1.1	nc	(nc-nc)
Female	117	137.7	85.0	(70.3-101.8)
Cervix Uteri				
Female	5	6.0	83.6	(27.0-195.2)
Colon / Rectum				
Male	80	55.8	143.5	(113.8-178.6)
Female	37	55.5	66.6	(46.9-91.8)
Esophagus				
Male	5	8.8	56.9	(18.3-132.8)
Female	1	2.7	nc	(nc-nc)
Hodgkin Lymphoma				
Male	4	3.0	nc	(nc-nc)
Female	2	2.5	nc	(nc-nc)
Kidney & Renal Pelvis				
Male	24	14.3	167.8	(107.5-249.7)
Female	11	9.5	115.4	(57.5-206.4)
Larynx				
Male	9	6.5	138.1	(63.0-262.2)
Female	1	1.7	nc	(nc-nc)
Leukemia				
Male	8	10.9	73.4	(31.6-144.6)
Female	4	9.1	nc	(nc-nc)
Liver and Intrahepatic Bile Ducts				
Male	6	6.6	90.3	(33.0-196.5)
Female	2	2.6	nc	(nc-nc)
Lung and Bronchus				
Male	58	71.0	81.7	(62.1-105.7)
Female	42	62.5	67.2	(48.4-90.8)

Male	15	18.0	83.3	(46.6-137.4)
Female	20	16.6	120.1	(73.4-185.6)
Oral Cavity & Pharynx				
Male	13	13.7	94.7	(50.4-161.9)
Female	3	6.7	nc	(nc-nc)
Ovary				
Female	15	14.1	106.1	(59.3-175.0)
Pancreas				
Male	15	10.4	144.4	(80.8-238.2)
Female	13	11.5	112.6	(59.9-192.6)
Prostate				
Male	167	148.2	112.7	(96.2-131.1)
Stomach				
Male	9	9.5	94.9	(43.3-180.2)
Female	9	5.8	154.1	(70.3-292.6)
Testis				
Male	2	4.8	nc	(nc-nc)
Thyroid				
Male	1	3.3	nc	(nc-nc)
Female	9	10.2	88.6	(40.4-168.3)
Uteri Corpus and Uterus, NOS				
Female	25	27.4	91.3	(59.1-134.8)
All Sites / Types				
Male	499	483.3	103.2	(94.4-112.7)
Female	407	453.3	89.8	(81.3-98.9)

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ( (Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- Shading indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

84

Dedham

Observed and Expected Case Counts, with Standardized Incidence Ratios, 1998-2002

	Obs	Exp	SIR	95% CI		Obs	Exp	SIR	95% CI
Bladder, Urinary					Melanoma of Skin				
Male	34	29.2	116.6	(80.7-162.9)	Male	13	14.2	91.2	(48.5-156.0)
Female	12	10.9	110.1	(56.8-192.3)	Female	13	11.3	115.5	(61.4-197.5)
Brain and Other Nervous System					Multiple Myeloma				
Male	4	5.3	nc	(nc-nc)	Male	5	4.0	124.6	(40.1-290.7)
Female	1	4.6	nc	(nc-nc)	Female	5	3.4	146.0	(47.1-340.7)
Breast					Non-Hodgkin Lymphoma				
Male	0	0.9	nc	(nc-nc)	Male	10	14.2	70.6	(33.8-129.8)
Female	114	109.0	104.6	(86.3-125.6)	Female	12	13.3	89.9	(46.4-157.1)
Cervix Uteri					Oral Cavity & Pharynx				
Female	4	4.9	nc	(nc-nc)	Male	14	10.5	133.0	(72.6-223.1)
Colon / Rectum					Female	0	5.4	nc	(nc-nc)
Male	53	44.7	118.6	(88.9-155.2)	Ovary				
Female	38	44.4	85.7	(60.6-117.6)	Female	12	11.2	107.3	(55.4-187.4)
Esophagus					Pancreas				
Male	5	6.9	72.3	(23.3-168.8)	Male	9	8.3	108.9	(49.7-206.7)
Female	1	2.2	nc	(nc-nc)	Female	12	9.3	129.5	(66.8-226.3)
Hodgkin Lymphoma					Prostate				
Male	4	2.2	nc	(nc-nc)	Male	111	117.2	94.7	(77.9-114.1)
Female	3	1.8	nc	(nc-nc)					

Kidney & Renal Pelvis					Stomach				
Male	15	11.2	133.9	(74.9-220.8)	Male	7	7.6	92.5	(37.1-190.7)
Female	6	7.7	78.4	(28.6-170.6)	Female	3	4.7	nc	(nc-nc)
Larynx					Testis				
Male	4	5.1	nc	(nc-nc)	Male	5	3.8	132.1	(42.6-308.2)
Female	0	1.4	nc	(nc-nc)					
Leukemia					Thyroid				
Male	6	8.7	69.3	(25.3-150.9)	Male	6	2.6	230.6	(84.2-502.0)
Female	9	7.3	122.9	(56.1-233.4)	Female	6	8.1	74.1	(27.1-161.3)
Liver and Intrahepatic Bile Ducts					Uteri Corpus and Uterus, NOS				
Male	7	5.2	134.6	(53.9-277.3)					
Female	4	2.1	nc	(nc-nc)	Female	21	21.7	96.6	(59.8-147.7)
Lung and Bronchus					All Sites / Types				
Male	60	56.9	105.4	(80.4-135.7)	Male	407	383.5	106.1	(96.1-117.0)
Female	60	50.5	118.8	(90.7-153.0)	Female	366	361.5	101.2	(91.1-112.2)

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ( (Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- Shading indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

85  
Deerfield

Observed and Expected Case Counts, with Standardized Incidence Ratios, 1998-2002

	Obs	Exp	SIR	95% CI		Obs	Exp	SIR	95% CI
Bladder, Urinary					Melanoma of Skin				
Male	4	5.7	nc	(nc-nc)	Male	5	3.0	166.6	(53.7-388.9)
Female	3	2.0	nc	(nc-nc)	Female	2	2.3	nc	(nc-nc)
Brain and Other Nervous System					Multiple Myeloma				
Male	1	1.1	nc	(nc-nc)	Male	0	0.8	nc	(nc-nc)

Breast	Female	1	0.9	nc	(nc-nc)
	Male	0	0.2	nc	(nc-nc)
Cervix Uteri	Female	17	22.6	75.3	(43.9-120.6)
	Male	0	0.2	nc	(nc-nc)
Colon / Rectum	Female	1	1.0	nc	(nc-nc)
	Male	9	8.9	101.1	(46.2-192.0)
Esophagus	Female	7	8.3	84.7	(33.9-174.5)
	Male	0	1.4	nc	(nc-nc)
Hodgkin Lymphoma	Female	0	0.4	nc	(nc-nc)
	Male	1	0.5	nc	(nc-nc)
Kidney & Renal Pelvis	Female	0	0.4	nc	(nc-nc)
	Male	2	2.4	nc	(nc-nc)
Larynx	Female	0	1.5	nc	(nc-nc)
	Male	1	1.1	nc	(nc-nc)
Leukemia	Female	0	0.3	nc	(nc-nc)
	Male	4	1.8	nc	(nc-nc)
Liver and Intrahepatic Bile Ducts	Female	0	1.4	nc	(nc-nc)
	Male	0	1.1	nc	(nc-nc)
Lung and Bronchus	Female	0	0.4	nc	(nc-nc)
	Male	0	0.2	nc	(nc-nc)

Non-Hodgkin Lymphoma	Female	1	0.6	nc	(nc-nc)
	Male	2	2.9	nc	(nc-nc)
Oral Cavity & Pharynx	Female	2	2.6	nc	(nc-nc)
	Male	1	2.3	nc	(nc-nc)
Ovary	Female	0	1.1	nc	(nc-nc)
	Male	0	0.4	nc	(nc-nc)
Pancreas	Female	1	2.3	nc	(nc-nc)
	Male	1	1.7	nc	(nc-nc)
Prostate	Female	0	1.7	nc	(nc-nc)
	Male	23	23.7	97.1	(61.5-145.7)
Stomach	Female	0	0.9	nc	(nc-nc)
	Male	0	1.5	nc	(nc-nc)
Testis	Female	0	0.8	nc	(nc-nc)
	Male	0	0.8	nc	(nc-nc)
Thyroid	Female	1	1.8	nc	(nc-nc)
	Male	1	0.6	nc	(nc-nc)
Uteri Corpus and Uterus, NOS	Female	3	4.4	nc	(nc-nc)
	Male	0	0.4	nc	(nc-nc)
All Sites / Types					



Male	5	11.3	44.4	(14.3-103.5)
Female	7	9.6	73.2	(29.3-150.9)

Male	64	77.7	82.4	(63.4-105.2)
Female	53	71.3	74.3	(55.6-97.2)

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ( (Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- Shading indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

86  
Dennis

Observed and Expected Case Counts, with Standardized Incidence Ratios, 1998-2002

	Obs	Exp	SIR	95% CI		Obs	Exp	SIR	95% CI
Bladder, Urinary					Melanoma of Skin				
Male	41	32.1	127.6	(91.5-173.1)	Male	27	13.5	200.3	(132.0-291.5)
Female	18	11.2	160.1	(94.9-253.1)	Female	16	9.6	167.5	(95.7-272.0)
Brain and Other Nervous System					Multiple Myeloma				
Male	5	4.5	110.6	(35.6-258.1)	Male	8	4.3	188.0	(81.0-370.5)
Female	7	4.0	175.7	(70.4-362.0)	Female	5	3.5	141.7	(45.7-330.7)
Breast					Non-Hodgkin Lymphoma				
Male	2	0.9	nc	(nc-nc)	Male	21	13.8	151.8	(93.9-232.0)
Female	126	100.0	125.9	(104.9-150.0)	Female	17	13.1	129.9	(75.6-207.9)
Cervix Uteri					Oral Cavity & Pharynx				
Female	6	3.8	158.3	(57.8-344.6)	Male	10	9.8	101.8	(48.7-187.2)
Colon / Rectum					Female	10	5.1	196.3	(94.0-361.1)
Male	42	48.3	87.0	(62.7-117.7)	Ovary				
Female	50	46.3	108.1	(80.2-142.5)	Female	16	10.4	153.8	(87.9-249.8)
Esophagus					Pancreas				
Male	8	7.1	112.2	(48.3-221.0)	Male	5	8.8	56.5	(18.2-131.9)
Female	3	2.3	nc	(nc-nc)	Female	10	9.7	102.7	(49.2-188.9)

Hodgkin Lymphoma					Prostate				
Male	0	1.5	nc	(nc-nc)	Male	169	122.4	138.1	(118.1-160.6)
Female	1	1.3	nc	(nc-nc)					
Kidney & Renal Pelvis					Stomach				
Male	7	11.0	63.8	(25.6-131.5)	Male	4	8.2	nc	(nc-nc)
Female	10	7.5	133.8	(64.1-246.1)	Female	3	4.9	nc	(nc-nc)
Larynx					Testis				
Male	3	5.1	nc	(nc-nc)	Male	1	1.9	nc	(nc-nc)
Female	0	1.3	nc	(nc-nc)					
Leukemia					Thyroid				
Male	6	8.5	70.5	(25.8-153.5)	Male	2	1.9	nc	(nc-nc)
Female	6	6.9	86.5	(31.6-188.2)	Female	7	5.7	122.1	(48.9-251.5)
Liver and Intrahepatic Bile Ducts					Uteri Corpus and Uterus, NOS				
Male	3	5.1	nc	(nc-nc)					
Female	1	2.1	nc	(nc-nc)	Female	18	20.4	88.3	(52.3-139.6)
Lung and Bronchus					All Sites / Types				
Male	52	61.2	84.9	(63.4-111.4)	Male	443	395.9	111.9	(101.7-122.8)
Female	57	51.3	111.1	(84.2-144.0)	Female	416	347.1	119.8	(108.6-131.9)

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ( (Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- Shading indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

87  
Dighton

Observed and Expected Case Counts, with Standardized Incidence Ratios, 1998-2002

	Obs	Exp	SIR	95% CI		Obs	Exp	SIR	95% CI
Bladder, Urinary					Melanoma of Skin				
Male	6	6.5	92.0	(33.6-200.3)	Male	0	3.4	nc	(nc-nc)

Brain and Other Nervous System	Female	1	2.3	nc	(nc-nc)
	Male	2	1.3	nc	(nc-nc)
Breast	Female	1	1.1	nc	(nc-nc)
	Male	1	0.2	nc	(nc-nc)
Cervix Uteri	Female	30	25.6	117.3	(79.1-167.5)
Colon / Rectum	Female	1	1.2	nc	(nc-nc)
	Male	13	10.1	128.3	(68.3-219.4)
Esophagus	Female	7	9.5	74.1	(29.7-152.6)
	Male	2	1.6	nc	(nc-nc)
Hodgkin Lymphoma	Female	1	0.5	nc	(nc-nc)
	Male	1	0.6	nc	(nc-nc)
Kidney & Renal Pelvis	Female	0	0.5	nc	(nc-nc)
	Male	2	2.7	nc	(nc-nc)
Larynx	Female	2	1.7	nc	(nc-nc)
	Male	2	1.2	nc	(nc-nc)
Leukemia	Female	1	0.3	nc	(nc-nc)
	Male	3	2.1	nc	(nc-nc)
Liver and Intrahepatic Bile Ducts	Female	1	1.6	nc	(nc-nc)

Multiple Myeloma	Female	3	2.7	nc	(nc-nc)
	Male	1	0.9	nc	(nc-nc)
Non-Hodgkin Lymphoma	Female	1	0.7	nc	(nc-nc)
	Male	11	3.4	325.8	(162.4-582.9)
Oral Cavity & Pharynx	Female	3	2.9	nc	(nc-nc)
	Male	4	2.6	nc	(nc-nc)
Ovary	Female	1	1.2	nc	(nc-nc)
	Female	5	2.6	193.1	(62.2-450.6)
Pancreas	Male	0	1.9	nc	(nc-nc)
	Female	1	2.0	nc	(nc-nc)
Prostate	Male	35	27.0	129.5	(90.2-180.1)
Stomach	Male	0	1.7	nc	(nc-nc)
	Female	0	1.0	nc	(nc-nc)
Testis	Male	0	1.0	nc	(nc-nc)
Thyroid	Male	2	0.7	nc	(nc-nc)
	Female	4	2.1	nc	(nc-nc)
Uteri Corpus and Uterus, NOS					

Male	1	1.2	nc	(nc-nc)					
Female	1	0.4	nc	(nc-nc)	Female	3	5.0	nc	(nc-nc)
Lung and Bronchus					All Sites / Types				
Male	17	12.9	132.3	(77.0-211.8)	Male	106	88.9	119.2	(97.6-144.2)
Female	13	10.9	119.8	(63.7-204.9)	Female	83	81.5	101.8	(81.1-126.2)

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ( (Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- Shading indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

88

Douglas

Observed and Expected Case Counts, with Standardized Incidence Ratios, 1998-2002

	Obs	Exp	SIR	95% CI		Obs	Exp	SIR	95% CI
Bladder, Urinary					Melanoma of Skin				
Male	4	4.9	nc	(nc-nc)	Male	5	3.0	167.9	(54.1-391.8)
Female	0	1.8	nc	(nc-nc)	Female	1	2.5	nc	(nc-nc)
Brain and Other Nervous System					Multiple Myeloma				
Male	2	1.2	nc	(nc-nc)	Male	1	0.7	nc	(nc-nc)
Female	1	1.0	nc	(nc-nc)	Female	0	0.5	nc	(nc-nc)
Breast					Non-Hodgkin Lymphoma				
Male	0	0.2	nc	(nc-nc)	Male	4	2.9	nc	(nc-nc)
Female	29	21.5	134.7	(90.2-193.4)	Female	0	2.4	nc	(nc-nc)
Cervix Uteri					Oral Cavity & Pharynx				
Female	1	1.2	nc	(nc-nc)	Male	3	2.2	nc	(nc-nc)
					Female	2	1.0	nc	(nc-nc)
Colon / Rectum					Ovary				
Male	8	7.8	102.2	(44.0-201.4)					
Female	3	7.3	nc	(nc-nc)	Female	0	2.2	nc	(nc-nc)

Esophagus						Pancreas				
Male	0	1.3	nc	(nc-nc)		Male	3	1.5	nc	(nc-nc)
Female	2	0.4	nc	(nc-nc)		Female	0	1.5	nc	(nc-nc)
Hodgkin Lymphoma						Prostate				
Male	1	0.6	nc	(nc-nc)		Male	15	20.1	74.6	(41.7-123.0)
Female	0	0.5	nc	(nc-nc)						
Kidney & Renal Pelvis						Stomach				
Male	0	2.2	nc	(nc-nc)		Male	2	1.4	nc	(nc-nc)
Female	1	1.4	nc	(nc-nc)		Female	1	0.8	nc	(nc-nc)
Larynx						Testis				
Male	2	1.0	nc	(nc-nc)		Male	0	1.2	nc	(nc-nc)
Female	0	0.2	nc	(nc-nc)						
Leukemia						Thyroid				
Male	2	1.8	nc	(nc-nc)		Male	0	0.7	nc	(nc-nc)
Female	0	1.4	nc	(nc-nc)		Female	3	2.2	nc	(nc-nc)
Liver and Intrahepatic Bile Ducts						Uteri Corpus and Uterus, NOS				
Male	0	1.0	nc	(nc-nc)						
Female	0	0.4	nc	(nc-nc)		Female	3	4.0	nc	(nc-nc)
Lung and Bronchus						All Sites / Types				
Male	6	9.7	62.0	(22.6-134.9)		Male	61	70.1	87.1	(66.6-111.9)
Female	5	8.2	61.2	(19.7-142.9)		Female	54	66.8	80.8	(60.7-105.5)

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ( (Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- Shading indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

	Obs	Exp	SIR	95% CI
Bladder, Urinary				
Male	5	6.5	76.9	(24.8-179.5)
Female	0	2.0	nc	(nc-nc)
Brain and Other Nervous System				
Male	2	1.3	nc	(nc-nc)
Female	3	1.0	nc	(nc-nc)
Breast				
Male	0	0.2	nc	(nc-nc)
Female	19	24.2	78.4	(47.2-122.4)
Cervix Uteri				
Female	0	1.1	nc	(nc-nc)
Colon / Rectum				
Male	10	10.2	98.4	(47.1-180.9)
Female	11	7.6	145.0	(72.3-259.5)
Esophagus				
Male	0	1.7	nc	(nc-nc)
Female	0	0.4	nc	(nc-nc)
Hodgkin Lymphoma				
Male	0	0.5	nc	(nc-nc)
Female	0	0.4	nc	(nc-nc)
Kidney & Renal Pelvis				
Male	1	2.8	nc	(nc-nc)
Female	2	1.5	nc	(nc-nc)
Larynx				
Male	1	1.3	nc	(nc-nc)
Female	0	0.3	nc	(nc-nc)
Leukemia				

	Obs	Exp	SIR	95% CI
Melanoma of Skin				
Male	3	3.4	nc	(nc-nc)
Female	7	2.4	288.6	(115.6-594.6)
Multiple Myeloma				
Male	0	0.9	nc	(nc-nc)
Female	1	0.6	nc	(nc-nc)
Non-Hodgkin Lymphoma				
Male	4	3.3	nc	(nc-nc)
Female	3	2.5	nc	(nc-nc)
Oral Cavity & Pharynx				
Male	2	2.7	nc	(nc-nc)
Female	3	1.1	nc	(nc-nc)
Ovary				
Female	4	2.4	nc	(nc-nc)
Pancreas				
Male	1	1.9	nc	(nc-nc)
Female	2	1.6	nc	(nc-nc)
Prostate				
Male	40	28.7	139.3	(99.5-189.7)
Stomach				
Male	4	1.7	nc	(nc-nc)
Female	0	0.8	nc	(nc-nc)
Testis				
Male	0	0.7	nc	(nc-nc)
Thyroid				

Male	2	2.0	nc	(nc-nc)	Male	1	0.6	nc	(nc-nc)
Female	0	1.4	nc	(nc-nc)	Female	4	1.9	nc	(nc-nc)
Liver and Intrahepatic Bile Ducts					Uteri Corpus and Uterus, NOS				
Male	0	1.3	nc	(nc-nc)					
Female	0	0.4	nc	(nc-nc)	Female	4	4.9	nc	(nc-nc)
Lung and Bronchus					All Sites / Types				
Male	3	13.1	nc	(nc-nc)	Male	83	90.4	91.8	(73.1-113.8)
Female	6	9.7	61.6	(22.5-134.1)	Female	73	73.0	100.0	(78.4-125.8)

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ( (Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- Shading indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

90									
Dracut									
Observed and Expected Case Counts, with Standardized Incidence Ratios, 1998-2002									
	Obs	Exp	SIR	95% CI		Obs	Exp	SIR	95% CI
Bladder, Urinary					Melanoma of Skin				
Male	32	25.3	126.3	(86.4-178.3)	Male	2	14.0	nc	(nc-nc)
Female	11	9.5	115.7	(57.7-207.0)	Female	12	11.8	101.7	(52.5-177.7)
Brain and Other Nervous System					Multiple Myeloma				
Male	4	5.6	nc	(nc-nc)	Male	4	3.6	nc	(nc-nc)
Female	5	4.7	107.0	(34.5-249.7)	Female	6	3.0	200.6	(73.3-436.7)
Breast					Non-Hodgkin Lymphoma				
Male	0	0.8	nc	(nc-nc)	Male	10	13.6	73.4	(35.1-134.9)
Female	102	107.8	94.6	(77.2-114.9)	Female	11	12.4	88.9	(44.3-159.0)
Cervix Uteri					Oral Cavity & Pharynx				
					Male	11	10.5	104.5	(52.1-187.0)
Female	4	5.4	nc	(nc-nc)	Female	6	5.1	118.0	(43.1-256.9)

Colon / Rectum					Ovary				
Male	35	39.6	88.4	(61.6-123.0)					
Female	49	37.8	129.7	(96.0-171.5)	Female	22	10.9	202.4	(126.8-306.4)
Esophagus					Pancreas				
Male	8	6.4	124.5	(53.6-245.2)	Male	6	7.4	81.1	(29.6-176.6)
Female	2	1.9	nc	(nc-nc)	Female	10	7.8	127.8	(61.2-235.0)
Hodgkin Lymphoma					Prostate				
Male	2	2.6	nc	(nc-nc)	Male	109	108.8	100.2	(82.3-120.9)
Female	2	2.2	nc	(nc-nc)					
Kidney & Renal Pelvis					Stomach				
Male	12	10.9	110.3	(57.0-192.8)	Male	6	6.7	90.1	(32.9-196.2)
Female	9	7.2	125.1	(57.1-237.6)	Female	2	3.9	nc	(nc-nc)
Larynx					Testis				
Male	6	4.8	123.8	(45.2-269.5)	Male	7	4.8	146.1	(58.5-301.0)
Female	1	1.3	nc	(nc-nc)					
Leukemia					Thyroid				
Male	6	8.4	71.9	(26.2-156.4)	Male	3	2.9	nc	(nc-nc)
Female	4	6.9	nc	(nc-nc)	Female	7	9.6	72.8	(29.2-150.1)
Liver and Intrahepatic Bile Ducts					Uteri Corpus and Uterus, NOS				
Male	4	5.0	nc	(nc-nc)					
Female	1	1.8	nc	(nc-nc)	Female	23	21.1	109.0	(69.1-163.5)
Lung and Bronchus					All Sites / Types				
Male	60	51.1	117.3	(89.5-151.0)	Male	346	355.7	97.3	(87.3-108.1)
Female	59	45.8	128.7	(98.0-166.0)	Female	378	341.2	110.8	(99.9-122.5)

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ( (Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- Shading indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;



## Observed and Expected Case Counts, with Standardized Incidence Ratios, 1998-2002

	Obs	Exp	SIR	95% CI		Obs	Exp	SIR	95% CI
Bladder, Urinary					Melanoma of Skin				
Male	9	10.3	87.5	(39.9-166.1)	Male	1	5.3	nc	(nc-nc)
Female	1	3.6	nc	(nc-nc)	Female	6	4.2	144.2	(52.6-313.8)
Brain and Other Nervous System					Multiple Myeloma				
Male	2	2.0	nc	(nc-nc)	Male	1	1.4	nc	(nc-nc)
Female	0	1.7	nc	(nc-nc)	Female	0	1.1	nc	(nc-nc)
Breast					Non-Hodgkin Lymphoma				
Male	0	0.3	nc	(nc-nc)	Male	2	5.3	nc	(nc-nc)
Female	34	39.0	87.2	(60.4-121.9)	Female	6	4.6	129.7	(47.4-282.4)
Cervix Uteri					Oral Cavity & Pharynx				
					Male	0	4.0	nc	(nc-nc)
Female	1	1.9	nc	(nc-nc)	Female	0	1.9	nc	(nc-nc)
Colon / Rectum					Ovary				
Male	13	15.9	81.9	(43.5-140.0)					
Female	14	14.8	94.7	(51.7-158.9)	Female	7	4.0	175.9	(70.5-362.4)
Esophagus					Pancreas				
Male	1	2.5	nc	(nc-nc)	Male	3	3.0	nc	(nc-nc)
Female	0	0.7	nc	(nc-nc)	Female	3	3.1	nc	(nc-nc)
Hodgkin Lymphoma					Prostate				
Male	0	0.9	nc	(nc-nc)	Male	34	41.8	81.4	(56.3-113.7)
Female	1	0.8	nc	(nc-nc)					
Kidney & Renal Pelvis					Stomach				
Male	1	4.1	nc	(nc-nc)	Male	2	2.7	nc	(nc-nc)
Female	2	2.7	nc	(nc-nc)	Female	2	1.5	nc	(nc-nc)
Larynx					Testis				

Male	2	1.9	nc	(nc-nc)	Male	0	1.6	nc	(nc-nc)
Female	2	0.5	nc	(nc-nc)					
Leukemia					Thyroid				
Male	4	3.2	nc	(nc-nc)	Male	1	1.0	nc	(nc-nc)
Female	1	2.6	nc	(nc-nc)	Female	3	3.2	nc	(nc-nc)
Liver and Intrahepatic Bile Ducts					Uteri Corpus and Uterus, NOS				
Male	0	1.9	nc	(nc-nc)					
Female	1	0.7	nc	(nc-nc)	Female	12	7.6	157.6	(81.3-275.2)
Lung and Bronchus					All Sites / Types				
Male	17	20.1	84.4	(49.1-135.1)	Male	101	138.4	73.0	(59.5-88.7)
Female	14	17.0	82.2	(44.9-138.0)	Female	118	126.2	93.5	(77.4-112.0)

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ( (Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- Shading indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

92

#### Dunstable

#### Observed and Expected Case Counts, with Standardized Incidence Ratios, 1998-2002

	Obs	Exp	SIR	95% CI		Obs	Exp	SIR	95% CI
Bladder, Urinary					Melanoma of Skin				
Male	0	2.1	nc	(nc-nc)	Male	4	1.3	nc	(nc-nc)
Female	1	0.7	nc	(nc-nc)	Female	0	1.1	nc	(nc-nc)
Brain and Other Nervous System					Multiple Myeloma				
Male	0	0.5	nc	(nc-nc)	Male	1	0.3	nc	(nc-nc)
Female	0	0.4	nc	(nc-nc)	Female	0	0.2	nc	(nc-nc)
Breast					Non-Hodgkin Lymphoma				
Male	0	0.1	nc	(nc-nc)	Male	1	1.2	nc	(nc-nc)
Female	8	9.7	82.3	(35.5-162.3)	Female	0	0.9	nc	(nc-nc)

Cervix Uteri						Oral Cavity & Pharynx				
	Female	0	0.5	nc	(nc-nc)	Male	1	1.1	nc	(nc-nc)
	Female					Female	1	0.4	nc	(nc-nc)
Colon / Rectum						Ovary				
	Male	2	3.4	nc	(nc-nc)					
	Female	2	2.5	nc	(nc-nc)	Female	0	0.9	nc	(nc-nc)
Esophagus						Pancreas				
	Male	1	0.6	nc	(nc-nc)	Male	0	0.6	nc	(nc-nc)
	Female	0	0.1	nc	(nc-nc)	Female	0	0.5	nc	(nc-nc)
Hodgkin Lymphoma						Prostate				
	Male	1	0.2	nc	(nc-nc)	Male	15	9.8	152.7	(85.4-251.9)
	Female	0	0.2	nc	(nc-nc)					
Kidney & Renal Pelvis						Stomach				
	Male	0	1.0	nc	(nc-nc)	Male	1	0.6	nc	(nc-nc)
	Female	0	0.6	nc	(nc-nc)	Female	0	0.3	nc	(nc-nc)
Larynx						Testis				
	Male	0	0.5	nc	(nc-nc)	Male	0	0.4	nc	(nc-nc)
	Female	0	0.1	nc	(nc-nc)					
Leukemia						Thyroid				
	Male	0	0.8	nc	(nc-nc)	Male	0	0.3	nc	(nc-nc)
	Female	1	0.5	nc	(nc-nc)	Female	0	1.0	nc	(nc-nc)
Liver and Intrahepatic Bile Ducts						Uteri Corpus and Uterus, NOS				
	Male	0	0.5	nc	(nc-nc)					
	Female	0	0.1	nc	(nc-nc)	Female	3	1.9	nc	(nc-nc)
Lung and Bronchus						All Sites / Types				
	Male	4	4.3	nc	(nc-nc)	Male	35	31.7	110.5	(77.0-153.7)
	Female	4	3.3	nc	(nc-nc)	Female	22	27.7	79.4	(49.7-120.2)

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ( (Obs / Exp) X 100);

- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- Shading indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

93

Duxbury

Observed and Expected Case Counts, with Standardized Incidence Ratios, 1998-2002

	Obs	Exp	SIR	95% CI		Obs	Exp	SIR	95% CI
Bladder, Urinary					Melanoma of Skin				
Male	14	14.9	94.2	(51.5-158.1)	Male	18	8.1	222.0	(131.5-350.9)
Female	6	5.5	108.5	(39.6-236.1)	Female	10	6.5	153.0	(73.3-281.5)
Brain and Other Nervous System					Multiple Myeloma				
Male	1	3.1	nc	(nc-nc)	Male	2	2.2	nc	(nc-nc)
Female	4	2.6	nc	(nc-nc)	Female	4	1.7	nc	(nc-nc)
Breast					Non-Hodgkin Lymphoma				
Male	1	0.5	nc	(nc-nc)	Male	4	7.8	nc	(nc-nc)
Female	59	64.3	91.8	(69.9-118.4)	Female	7	7.0	100.7	(40.3-207.5)
Cervix Uteri					Oral Cavity & Pharynx				
Female	0	2.9	nc	(nc-nc)	Male	4	6.6	nc	(nc-nc)
					Female	2	3.0	nc	(nc-nc)
Colon / Rectum					Ovary				
Male	31	23.4	132.7	(90.1-188.3)					
Female	23	22.5	102.1	(64.7-153.2)	Female	4	6.4	nc	(nc-nc)
Esophagus					Pancreas				
Male	1	3.9	nc	(nc-nc)	Male	6	4.4	135.5	(49.5-294.9)
Female	2	1.1	nc	(nc-nc)	Female	5	4.6	108.2	(34.9-252.5)
Hodgkin Lymphoma					Prostate				
Male	2	1.2	nc	(nc-nc)	Male	91	65.0	139.9	(112.7-171.8)
Female	2	1.0	nc	(nc-nc)					
Kidney & Renal Pelvis					Stomach				

Larynx	Male	3	6.5	nc	(nc-nc)	Testis	Male	1	4.0	nc	(nc-nc)
	Female	7	4.1	171.4	(68.7-353.1)		Female	0	2.4	nc	(nc-nc)
Leukemia	Male	2	3.0	nc	(nc-nc)	Thyroid	Male	3	1.9	nc	(nc-nc)
	Female	2	0.7	nc	(nc-nc)		Female	6	5.0	120.2	(43.9-261.7)
Liver and Intrahepatic Bile Ducts	Male	9	4.7	189.6	(86.5-360.0)	Uteri Corpus and Uterus, NOS	Male	1	1.6	nc	(nc-nc)
	Female	4	4.0	nc	(nc-nc)		Female	18	12.6	143.1	(84.8-226.2)
Lung and Bronchus	Male	2	3.0	nc	(nc-nc)	All Sites / Types	Male	235	208.6	112.6	(98.7-128.0)
	Female	1	1.1	nc	(nc-nc)		Female	214	198.6	107.8	(93.8-123.2)
	Male	24	29.8	80.6	(51.6-119.9)		Male	235	208.6	112.6	(98.7-128.0)
	Female	30	25.4	118.1	(79.7-168.6)		Female	214	198.6	107.8	(93.8-123.2)

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ( (Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- Shading indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;